CCS Perioperative Guidelines When to order a BNP and What to do with a Positive Troponin

Similar documents
Myocardial Injury after Noncardiac Surgery (MINS): What is it and what can we do to help patients suffering this event? PJ Devereaux, MD, PhD

Clinical Controversies in Perioperative Medicine

Preoperative Cardiac Evaluation:

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Peri-operative Troponin Measurements - Pathophysiology and Prognosis

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC. DO's and DON'Ts: Reducing unnecessary perioperative investigations

PERIOPERATIVE EVALUATION AND ANESTHETIC MANAGEMENT OF PATIENTS WITH CARDIAC DISEASE FOR NON CARDIAC SURGERY

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Perioperative Infarcts: Epidemiology, predictors and post-op monitoring

Clinical Controversies in Perioperative Medicine

8/28/2018. Pre-op Evaluation for non cardiac surgery. A quick review from 2007!! Disclosures. John Steuter, MD. None

by Brian Wolfe, MD Assistant Professor of Medicine, University of Colorado Denver

Clinical Controversies in Perioperative Medicine

Agenda. Disclosures. Surgical Mortality: What is High Risk?

Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D.

Update on Perioperative Medicine. Update on Perioperative Medicine. Question 1: Clinical Risk Prediction. for the Office-based Practitioner

Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington

Cardiac Screening with Electrocardiography, Stress Echocardiography, or Myocardial Perfusion Imaging

Preoperative Cardiac Risk Assessment: Approach & Guidelines

Evaluating the Heart before Non-Cardiac Surgery

PERIOPERATIVE CARDIAC RISK ASSESSMENT. Divya Gollapudi, MD

Current and Future Imaging Trends in Risk Stratification for CAD

Cardiac Risk Assessment in the Preoperative period

HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD

Perioperative Myocardial Infarction

Preoperative Cardiac Risk Calculators

Avoiding Thor s Thunderbolt!

Perioperative Medical Therapy: Beta Blockers, Statins, ACE-Inhibitors, ARB Effects on Mortality

SUPPLEMENTARY DOCUMENTS. Supplemental Table 1: Panel members GRADE of recommendation rating and conflicts

Transfusion triggers in acute coronary syndromes: The MINT trial

Low Risk Chest Pain. Objectives. Disclosure. Case 1. Jeffrey Tabas, MD Professor of Emergency Medicine Office of CME UCSF School of Medicine

Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD

Agenda. Perioperative Cardiac Risk Stratification circa Surgical Mortality: What is High Risk? Presenter Disclosure Information

David A. Orsinelli, MD, FACC, FASE Professor, Internal Medicine The Ohio State University Division of Cardiovascular Medicine Columbus, Ohio

Preoperative Risk. Geoffrey C Zarrella DO FACC. Assessment

Clinical Controversies in Perioperative Medicine!

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

Pre-op Risk Assessment. Hal Blanks MD FACC

Biomarkers in cardiovascular disease. Felix J. Rogers, DO, FACOI April 29, 2018

Ischemic and bleeding risk stratification in NSTE ACS. Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland

Preoperative Evaluation Guidelines and Work up

Stress Testing:Which Study is Indicated for My Patient?

Update in Perioperative Medicine

Perioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease

Perioperative Cardiac Management. Emma Sargsyan, MD, FACP

Severe aortic stenosis should be operated before symptom onset CONTRA. Helmut Baumgartner

Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, MD, FHRS

Updates & Controversies in Perioperative Medicine

Mario Plebani University-Hospital of Padova, Italy

DECLARATION OF CONFLICT OF INTEREST

Post Operative Troponin Leak: David Smyth Christchurch New Zealand

Judicious Use of Preoperative Consultants. Relevant disclosures: None. Preoperative Consultation by Specialists: Overall Impact on Outcome?

A few years ago my team was consulted to clear a patient for surgery. I said OK, let s get a pre-op consult note on the chart.

Simon A. Mahler MD, MS, FACEP Associate Professor Department of Emergency Medicine Wake Forest School of Medicine

SESSION 5 2:20 3:35 pm

High-Sensitivity Cardiac Troponin in Suspected ACS

PERIOPERATIVE MYOCARDIAL INFARCTION THE ANAESTHESIOLOGIST'S VIEW

Q: Do cardiac risk stratification indexes

Guidelines PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42. Prominent Dutch Cardiovascular Researcher Fired for Scientific Misconduct

Corporate Medical Policy

Perioperative Medicine 2016 Some Answers, Even More Questions

Blood transfusions in ICU: double-edged sword. Paul Hébert, MD MHSc(Epid) Physician-in-Chief, CHUM Professor, University of Montreal

Timing of Surgery After Percutaneous Coronary Intervention

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

Är dagens troponinmetoder tillräckligt känsliga?

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group

Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018

Troponin = 35. Objectives. Low Risk Chest Pain. Does this patient have ACS? Does this patient have ACS? Objectives


Patient characteristics Intervention Comparison Length of followup

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

An update on the management of UA / NSTEMI. Michael H. Crawford, MD

Preoperative Evaluation: Patients with Cardiac Disease

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy

Evaluation and Management of the Patient with Cardiac Disease for Non-Cardiac Surgery WINTER CONFRENCE 2016 RONY GORGES, MD

Which Test When? Avoid the Stress of Stress Testing. Marc Newell, MD, FACC, FSCCT Minneapolis Heart Institute

Testing the Asymptomatic CAD Patient: When and Why?

Canadian Antiplatelet Therapy Guidelines: 2014 Update James D. Douketis MD, FRCP(C)

High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU

Chest Pain in Women ;What is Your Diagnostic Plan? No Need for Noninvasive Test

Diabetes and the Heart

Value of troponin measurements in carotid artery revascularization

High Sensitivity Troponin Improves Management. But Not Yet

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

Learning Objectives. Predicting and Preventing Cardiovascular Disease. ACC/AHA Cholesterol Guidelines Key differences vs ATP III

Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures

Optimal testing for coronary artery disease in symptomatic and asymptomatic patients

4/27/2015. Cardiac Events #1 cause of postoperative complications/ mortality- CHF, complete heart block, MI,

The ACC Heart Failure Guidelines

Biomarkers in Heart Disease. Felix J. Rogers, DO, FACOI April 29, 2018

2/20/2013. Why use imaging in CV prevention? Update on coronary CTA in 2013 Coronary CTA for 1 0 prevention: pros and cons Are we there yet?

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Biomarkers in the Assessment of Congestive Heart Failure

Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON

2/26/2013. NCDR.13 Case Scenario Presentation Cath PCI Registry. Disclosures. Objectives. Dashboard Implications of Some Major Metrics

UPDATES IN MANAGEMENT OF HF

Prognostic capabilities of coronary computed tomographic angiography before non-cardiac surgery: prospective cohort study

Financial Disclosures. Coronary Artery Calcification. Objectives. Coronary Artery Calcium 6/6/2018. Heart Disease Statistics At-a-Glace 2017

Transcription:

Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON CCS Perioperative Guidelines When to order a BNP and What to do with a Positive Troponin Dr. Vikas Tandon Associate Professor, Cardiology McMaster University November 1, 2017

CSIM Annual Meeting 2017 Conflict Disclosures I have the following conflicts to declare: Company/Organization Advisory Board or equivalent X X Details Speakers bureau member X X Payment from a commercial organization. (including gifts or other consideration or in kind compensation) X X Grant(s) or an honorarium X X Patent for a product referred to or X X marketed by a commercial organization. Investments in a pharmaceutical organization, medical devices company or communications firm. X Participating or participated in a clinical trial McMaster University Participated in periop research studies including VISION, POISE-2, MANAGE X

CSIM Annual Meeting 2017 The following presentation represents the views of the speaker at the time of the presentation. This information is meant for educational purposes, and should not replace other sources of information or your medical judgment. Learning Objectives: Understand the importance of perioperative risk assessment Review the utility of current risk stratification tools Examine the utility of BNP/nt-pro-BNP in the preoperative setting Understand the significance of the postoperative troponin elevation and develop an approach to management

Perioperative Care Congress: Science, Evidence and Practice Save the date: Perioperative Care Congress 2018 May 11-13, 2018 Toronto, Ontario CANADA Visit our website http://periopcongress.org/ or follow us on twitter @periopcongress More information to follow!

Case Mrs. B.W. 72 y/o F with significant OA Referred for upcoming total knee arthroplasty Cardiac risk factors DM, HTN, Chol, previous NSTEMI 2003 Otherwise asymptomatic, N vitals, N labs Meds: ASA, Atorvastatin, Coversyl, Bisoprolol OR date July 19, 2016

Case Mrs. B.W. What should be done next? 1. Send for cath 2. Take pt straight to the OR, no other consult required 3. Cancel surgery too high risk 4. Consider for a perioperative consult by medicine and/or cardiology teams

Is the preoperative consult useful?

Scope of problem Worldwide >200,000,000 major noncardiac surgical procedures annually 1:20 suffer myocardial injury/infarction or cardiac arrest/death within 30 days Perioperative cardiac complications account for 1/3 of perioperative deaths

Is the preoperative consult useful?

Yes! Is the preoperative consult useful? 1. Patients: ethical obligation to patients to give accurate risk assessment for informed decision making 2. Physicians: Gauge CV risk to guide management Further testing if needed Instructions re: medications Postop monitoring Shared care model

Good Pre-op Consults Specify: 1. Clear estimation of risk 2. Clear recommendation re: further testing 3. Clear recommendations for medications 4. Clear direction as to degree of post op monitoring i.e. ward bed w tele vs CCU/ICU/Step down bed, trops 5. Clear communication of who will do what

Risk Scores RCRI most validated; simplest to use CAD, stroke, CHF, DM, high risk surgery, Creatinine Does not take into account emergency surgeries underestimates cardiac risk by 50% NSQIP likely superior to RCRI Requires an online calculator Underestimates risk as routine troponin screening not done All risk scores will underestimate in >40% pts Limited mobility so pts won t manifest symptoms

CCS Recommendation When evaluating cardiac risk, we suggest clinicians use RCRI over other available clinical risk prediction scores Conditional recommendation low-quality evidence

Revised Cardiac Risk Index Variables Pts Hx of IHD 1 Hx of CHF 1 Hx of CVD 1 Insulin for diabetes 1 Crt >177 µmol/l 1 High-risk surgery 1 Total RCRI points Risk of MI, cardiac arrest, or death 30 days after surgery 95% CI 0 3.9% 2.8%-5.4% 1 6.0% 4.9%-7.4% 2 10.1% 8.1%-12.6% 3 15.0% 11.1%-20.0% * based on high-quality external validation studies

Is Non-Invasive Testing Useful? Current guidelines: Pts with low functional capacity Pts with risk of MI/death 1% When result will change management Stress Nuclear and Stress Echo most common 9% of adults age 40 with int/high risk tested

Pharmacological stress echocardiography and radionuclide imaging Several studies, mostly small sample size and small number of events Low quality of evidence most retrospective, few reported risk adjusted associations No study adequately assessed incremental value of stress tests over well-established perioperative cardiac risk factors (e.g., RCRI)

CCS Recommendations We recommend against performing preoperative exercise stress test, pharmacological stress echocardiography, or preoperative radionuclide imaging to enhance perioperative cardiac risk estimation

Is Cardiac CT Angiography Useful?

VISION CCTA Prospective cohort study 12 centers in 8 countries Evaluated whether preop CCTA enhances perioperative risk prediction in 955 at-risk patients Physicians were blinded unless LM detected Systematic Postop Trop monitoring Primary outcome - CV death and nonfatal MI 74 patients (7.7%) within 30 days of surgery

Interpretation of VISION CCTA results Although CCTA findings improve risk estimation for patients who will suffer periop CV death or MI CCTA findings are more than 5 X as likely to lead to inappropriate overestimation of risk among patients who will not suffer these outcomes

CCS Recommendation We recommend against performing preoperative coronary CT angiography to enhance perioperative cardiac risk estimation Strong recommendation, moderate-quality evidence

Biomarkers NT pro-bnp

Individual data M-A of 2179 patients 235 suffered death or MI within 30 days after noncardiac surgery Preop NT-proBNP 300 ng/l or BNP 92 ng/l strongest independent preop predictor of death/mi OR, 3.40; 95% CI, 2.57-4.47 Compared to preop clinical model preop natriuretic peptide improved risk estimation among patients who did and did not suffer primary outcome In sample of 1000 patients overall absolute NRI is 155 patients

NT-proBNP/BNP Risk of death or MI at 30 days after noncardiac surgery, based on patient s preoperative NT-proBNP or BNP Test result Risk estimate 95% CI NT-proBNP <300 ng/l or BNP <92 mg/l 4.9% 3.9% - 6.1% NT-proBNP value 300 ng/l or BNP 92 mg/l 21.8% 19.0% - 24.8% compared to RCRI, preop NT-proBNP/BNP results improved risk classification in 155 patients in 1000 patient sample based on risk categories <5%, 5-10%, >10-15%, >15%

Biomarkers NT pro-bnp Compared to imaging, NT pro-bnp More accurate Less expensive Convenient and faster due to availability of point of care NT pro-bnp assays due to cost differential b/w NT pro-bnp and consult may have role in determining who needs preop consult

CCS Recommendation We recommend measuring NT-proBNP or BNP before noncardiac surgery to enhance perioperative cardiac risk estimation in patients 65 years of age, 45 to 64 years of age with significant cardiovascular disease, or who have RCRI score 1 Strong recommendation, moderate-quality evidence

x

Case Mrs. B.W. 72 y/o F with significant OA Referred for upcoming total knee arthroplasty Cardiac risk factors DM, HTN, Chol, previous NSTEMI 2003 Otherwise asymptomatic, N vitals, N labs Meds: ASA, Atorvastatin, Coversyl, Bisoprolol OR date July 19, 2016

x

Troponin monitoring POISE Trial (8351 patients) 65% of patients suffering perioperative MI do not experience ischemic symptoms Presence or absence of signs/symptoms does not change risk 30-day mortality symptomatic MI: aor 4.76 (95% CI, 2.68-8.43) asymptomatic MI: aor 4.00 (95% CI, 2.65-6.06)

VISION Study (Botto 2014) Prospective international cohort study 15,065 in-hospital noncardiac surgery patients TnT measured postop days 1,2,3 MINS Criteria TnT 0.03 ng/ml due to myocardial ischemia death at 30 days: MINS - 9.8%, No MINS - 1.1% 84% MINS asymptomatic undetected without troponin monitoring Asymptomatic perioperative TnT elevations adjudicated as myocardial injuries due to ischemia that did not fulfill Universal Definition of MI were also associated with increased risk of 30-day mortality ahr, 3.30; 95% CI, 2.26 4.81

Recommendation We recommend obtaining daily troponin measurements for 48 to 72 hours after noncardiac surgery in patients with baseline risk >5%* for cardiovascular death or nonfatal MI at 30 days after surgery Strong recommendation, moderate-quality evidence * Patients with an elevated NT-proBNP/BNP measurement before surgery or, if there is no NT-proBNP/BNP measurement before surgery, in those who have an RCRI score 1, age 45 to 64 years with significant cardiovascular disease, or age 65 years

Approach to MINS Look for and correct physiological abnormalities hypoxia, hypotension, tachycardia (if BP adequate), Hb if <70 If no signs of bleeding initiate ASA 81 mg daily Initiate or intensify Statin therapy

Postoperative management of complications ASA and statin in patients suffering myocardial injury after noncardiac surgery Prospective cohort study 415 noncardiac surgery patients who suffered postop MI ASA and statin at discharge reduced 30-day mortality ASA : aor 0.54 (95% CI, 0.29-0.99) Statin: aor 0.26 (95% CI, 0.13-0.54)

Recommendations We recommend initiation of long-term ASA and statin in patients who suffer myocardial injury or myocardial infarction after noncardiac surgery Strong recommendation, moderate-quality evidence

Case Mrs. B.W. 72 y/o F with significant OA Referred for upcoming total knee arthroplasty Cardiac risk factors DM, HTN, Chol, previous NSTEMI 2003 Otherwise asymptomatic, N vitals, N labs Meds: ASA, Atorvastatin, Coversyl, Bisoprolol Follow up 1, 6, 12, (18, 24) months

Conclusions 1. Current clinical risk scores underestimate risk in substantial proportion of patients Revised risk estimations for RCRI in new CCS guidelines Non-invasive testing probably adds little CCTA has net overall effect of putting more patients in wrong risk category 2. NT pro-bnp is more accurate, convenient, faster, and less expensive than non-invasive testing 3. Troponin are strong independent predictor of 30-day mortality after noncardiac surgery 85% of MINS patients asymptomatic (4 TH gen trop) Up to 93% asymptomatic with hs-trops 4. ASA and Statins reduce 30 day mortality in patients with MINS

CSIM Annual Meeting 2017 Special thanks to Dr. PJ Devereaux Scientific Leader, Perioperative Research Group, PHRI, McMaster University VISION, POISE 1, POISE 2 MANAGE, HIP ATTACK, VISION 2, POISE 3 Co-Chair, CCS Perioperative Guidelines

Comments and Questions

M-A of dipyridamole stress perfusion prior to vascular surgery

M-A of dipyridamole stress perfusion prior to vascular surgery Baseline risk = 7%

M-A of dipyridamole stress perfusion prior to vascular surgery Baseline risk = 7%

M-A of dipyridamole stress perfusion prior to vascular surgery Baseline risk = 7%

M-A of dipyridamole stress perfusion prior to vascular surgery Baseline risk = 7%

M-A of dipyridamole stress perfusion prior to vascular surgery Baseline risk = 7%

M-A of dipyridamole stress perfusion prior to vascular surgery Baseline risk = 7%

Is Non-Invasive Testing Useful? Limitations: Small studies, few events, clinicians not blinded Almost half used a retrospective design No evaluation independent prognostic value Few systematically monitored for MI None reporting net absolute reclassification

Net Absolute Reclassification Index how well a new model reclassifies subjects - either appropriately or inappropriately - as compared to an old model i.e. comparison of old model vs. old model + 1 new element RCRI alone vs. RCRI + non invasive test

Is Cardiac CT Angiography Useful?

VISION CCTA Prospective cohort study 12 centers in 8 countries Evaluated whether preop CCTA enhances perioperative risk prediction in 955 at-risk patients Physicians were blinded unless LM detected Systematic Postop Trop monitoring Primary outcome - CV death and nonfatal MI 74 patients (7.7%) within 30 days of surgery

Model with CCTA and RCRI - C=0.66 # of Patients HR 95% CI P RCRI scores 0 1 2 3 CCTA findings Normal Non-obst Obstructive Extensive obst 320 407 178 50 81 371 357 146 1.00 1.39 (0.74-2.61) 1.88 (0.94-3.79) 4.02 (1.80-8.98) 1.00 1.51 (0.45-5.10) 2.05 (0.62-6.74) 3.76 (1.12-12.62) 0.005-0.300 0.076 <0.001 0.014-0.509 0.238 0.032

Model with CCTA and RCRI - C=0.66 # of Patients HR 95% CI P RCRI scores 0 1 2 3 CCTA findings Normal Non-obst Obstructive Extensive obst 320 407 178 50 81 371 357 146 1.00 1.39 (0.74-2.61) 1.88 (0.94-3.79) 4.02 (1.80-8.98) 1.00 1.51 (0.45-5.10) 2.05 (0.62-6.74) 3.76 (1.12-12.62) 0.005-0.300 0.076 <0.001 0.014-0.509 0.238 0.032

Net reclassification index Models for 30 day probability of CV death and MI Model that included CCTA findings Patients who had an event Patients who did not have an event RCRI only <5% 5-15% >15% <5% 5-15% >15% <5% 5 10 0 191 114 0 5-15% 0 41 7 47 453 37 >15% 0 1 10 0 10 29 NRI for those who had event: 21.6% 95% CI 10.4-32.9) p<0.001 NRI for those who did not have event: -10.7% (-13.9- -7.5) p<0.001 Overall NRI: 11% (-0.73, 22.64), p=0.066

Net reclassification index Models for 30 day probability of CV death and MI Model that included CCTA findings Patients who had an event Patients who did not have an event RCRI only <5% 5-15% >15% <5% 5-15% >15% <5% 5 10 0 191 114 0 5-15% 0 41 7 47 453 37 >15% 0 1 10 0 10 29

Net reclassification index Models for 30 day probability of CV death and MI Model that included CCTA findings Patients who had an event Patients who did not have an event RCRI only <5% 5-15% >15% <5% 5-15% >15% <5% 5 10 0 191 114 0 5-15% 0 41 7 47 453 37 >15% 0 1 10 0 10 29

Net reclassification index Models for 30 day probability of CV death and MI Model that included CCTA findings Patients who had an event Patients who did not have an event RCRI only <5% 5-15% >15% <5% 5-15% >15% <5% 5 10 0 191 114 0 5-15% 0 41 7 47 453 37 >15% 0 1 10 0 10 29

Net reclassification index Models for 30 day probability of CV death and MI Model that included CCTA findings Patients who had an event Patients who did not have an event RCRI only <5% 5-15% >15% <5% 5-15% >15% <5% 5 10 0 191 114 0 5-15% 0 41 7 47 453 37 >15% 0 1 10 0 10 29

Net reclassification index Models for 30 day probability of CV death and MI Model that included CCTA findings Patients who had an event Patients who did not have an event RCRI only <5% 5-15% >15% <5% 5-15% >15% <5% 5 10 0 191 114 0 5-15% 0 41 7 47 453 37 >15% 0 1 10 0 10 29 17 pts appropriately reclassified 1 pt inappropriately reclassfied Net = 17-1 =16

Net reclassification index Models for 30 day probability of CV death and MI Model that included CCTA findings Patients who had an event Patients who did not have an event RCRI only <5% 5-15% >15% <5% 5-15% >15% <5% 5 10 0 191 114 0 5-15% 0 41 7 47 453 37 >15% 0 1 10 0 10 29 17 pts appropriately reclassified 1 pt inappropriately reclassfied Net = 17-1 =16

Net reclassification index Models for 30 day probability of CV death and MI Model that included CCTA findings Patients who had an event Patients who did not have an event RCRI only <5% 5-15% >15% <5% 5-15% >15% <5% 5 10 0 191 114 0 5-15% 0 41 7 47 453 37 >15% 0 1 10 0 10 29 17 pts appropriately reclassified 1 pt inappropriately reclassfied Net = 17-1 =16

Net reclassification index Models for 30 day probability of CV death and MI Model that included CCTA findings Patients who had an event Patients who did not have an event RCRI only <5% 5-15% >15% <5% 5-15% >15% <5% 5 10 0 191 114 0 5-15% 0 41 7 47 453 37 >15% 0 1 10 0 10 29 17 pts appropriately reclassified 1 pt inappropriately reclassfied Net = 17-1 =16

Net reclassification index Models for 30 day probability of CV death and MI Model that included CCTA findings Patients who had an event Patients who did not have an event RCRI only <5% 5-15% >15% <5% 5-15% >15% <5% 5 10 0 191 114 0 5-15% 0 41 7 47 453 37 >15% 0 1 10 0 10 29 17 pts appropriately reclassified 57 pts appropriately reclassified 1 pt inappropriately reclassfied 151 pts inapprop. reclassified Net = 17-1 = 16 Net = 57-151 = -94

Interpretation of VISION CCTA results Although CCTA findings improve risk estimation for patients who will suffer periop CV death or MI CCTA findings are more than 5 X as likely to lead to inappropriate overestimation of risk among patients who will not suffer these outcomes

CCS Recommendation We recommend against performing preoperative coronary CT angiography to enhance perioperative cardiac risk estimation Strong recommendation, moderate-quality evidence